Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Jun 02, 2021 11:36am
83 Views
Post# 33310824

RE:Shift - Our new media partner and our new rep

RE:Shift - Our new media partner and our new rep

Global Reach

SHIFT is agile enough to out-think, out-hustle and out-perform the huge holding-company agencies, yet big enough to have the relationships clients need and have access to literally any resource they may require.

As part of AVENIR GLOBAL, a top-15 worldwide communications network of agencies, we seamlessly connect with our six sister agencies and 1,000+ colleagues around the world to deliver the bespoke service and support our clients need.



LithLover wrote:

Kristin Villiotte

Vice President, Healthcare

As Vice President of SHIFT’s Healthcare practice, Kristin provides senior communications strategy and counsel for companies across the healthcare spectrum. She has more than 15 years of experience developing and executing creative communications programs that support increased brand awareness, corporate visibility, scientific exchange and competitive positioning. Throughout her career, Kristin has helped healthcare, medical device, health technology and biopharmaceutical industry clients gain valuable market visibility through impactful, integrated communications campaigns. She has represented a broad range of companies — from innovative startups to global pharmaceutical brands — including Merck/EMD Serono, Welltok and Healthify.

https://www.shiftcomm.com/
 

For further information please contact:

Investor Relations
Rebecca Greco
Tel: 1-855-420-7140 ext. 1838
rgreco@stagezerols.com

Media Contact
Kristin Villiotte
SHIFT Communications
kvilliotte@shiftcomm.com

 



<< Previous
Bullboard Posts
Next >>